Home > Journals > Minerva Medica > Past Issues > Minerva Medica 2003 October;94(5) > Minerva Medica 2003 October;94(5):353-8

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA MEDICA

A Journal on Internal Medicine


Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,236


eTOC

 

THERAPEUTICAL NOTES  


Minerva Medica 2003 October;94(5):353-8

language: English

Efficacy of disodium-clodronate in the management of joint pain in rheumatoid arthritis. Six months open study

Rovetta G., Monteforte P.


PDF  


Aim. The aim of the study was to evaluate the effect on the articular pain of 100 mg of disodium-clodronate administered for 6 days a week by intramuscular injection in rheumatoid arthritis (RA) patients.
Methods. We studied 46 patients (38 females and 8 males middle age 57±6.2 years, range from 30 to 80 years) with established RA, in the II and III anatomical stage according to Steinbrocker. Therapeutic regimen was for all patients oral methotrexate 7.5 mg weekly, prednisone 7.5 mg/day and AINS. All of these patients also received disodium-clodronate 100 mg for 6 days a week for 6 months. The results of the VAS for pain, the patient global assessment and the physician global assessment on disease activity have been recorded at baseline, at the 2 months and at 6 months of therapy.
Results. VAS for pain and patient global assessment of disease activity values decreased significantly after 2 months of therapy (pConclusion. Disodium-clodronate may be considered an adjunctive therapy in the pain management of RA patients.

top of page

Publication History

Cite this article as

Corresponding author e-mail